DiaMedica Therapeutics, Inc.
DiaMedica-Logo
Navigate DiaMedica Therapeutics, Inc.
Home
About Us
Company Overview
Leadership Team
Board of Directors
Clinical Advisory Boards
Science
Our Science
Pipeline
Diseases We Target
Overview
IgA Nephropathy
African Americans - Hypertensive with CKD
Acute Ischemic Stroke
Investors & Media
Investors Home
Press Releases
Events & Presentations
Nasdaq Stock Information
Analyst Coverage
Financial Reports
Governance
Investor Resources
Careers
Contact
Home
News
News
All News
By Year:
2020
2019
2018
2017
2016
Feb 22, 2018
DiaMedica Announces First Enrollment in its PHASE 2 “REMEDY” TRIAL for Acute Ischemic Stroke
Jan 29, 2018
DiaMedica to Present at the 14th Annual Noble Investor Conference
Jan 18, 2018
DiaMedica Letter to Shareholders
Dec 21, 2017
DiaMedica Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
Dec 18, 2017
DiaMedica Therapeutics Completes Non-Brokered Private Placement
Dec 13, 2017
DiaMedica Therapeutics Announces Non-Brokered Private Placement
Nov 22, 2017
DiaMedica Therapeutics Announces Ethics Committee Clearance at First Site to Initiate REMEDY Phase 2 Trial for Acute Ischemic Stroke
Nov 7, 2017
DiaMedica Therapeutics Announces Publication of Positive Clinical Results for DM199 in the International Journal of Clinical Trials
Oct 31, 2017
DiaMedica Announces Dr. Robert Stanton as Scientific Advisor for Upcoming Chronic Kidney Disease Trials
Oct 27, 2017
DiaMedica Therapeutics Announces the Early Exercise of Warrants from Strategic Investor
« Previous
1
2
3
4
5
6
7
8
9
Next »